NO20032531L - Tetralon-derivater som antitumormidler - Google Patents
Tetralon-derivater som antitumormidlerInfo
- Publication number
- NO20032531L NO20032531L NO20032531A NO20032531A NO20032531L NO 20032531 L NO20032531 L NO 20032531L NO 20032531 A NO20032531 A NO 20032531A NO 20032531 A NO20032531 A NO 20032531A NO 20032531 L NO20032531 L NO 20032531L
- Authority
- NO
- Norway
- Prior art keywords
- alkyl
- amino
- hydrogen
- compounds
- alkylene chain
- Prior art date
Links
- XHLHPRDBBAGVEG-UHFFFAOYSA-N 1-tetralone Chemical class C1=CC=C2C(=O)CCCC2=C1 XHLHPRDBBAGVEG-UHFFFAOYSA-N 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- -1 trifluoromethyl- Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 102000003964 Histone deacetylase Human genes 0.000 abstract 1
- 108090000353 Histone deacetylase Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000005530 alkylenedioxy group Chemical group 0.000 abstract 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D295/116—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings with the doubly bound oxygen or sulfur atoms directly attached to a carbocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00126820 | 2000-12-07 | ||
| PCT/EP2001/014311 WO2002046144A1 (en) | 2000-12-07 | 2001-12-06 | Tetralone derivatives as antitumor agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20032531D0 NO20032531D0 (no) | 2003-06-04 |
| NO20032531L true NO20032531L (no) | 2003-06-04 |
Family
ID=8170594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20032531A NO20032531L (no) | 2000-12-07 | 2003-06-04 | Tetralon-derivater som antitumormidler |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6531472B2 (bg) |
| EP (1) | EP1349830A1 (bg) |
| JP (1) | JP4091431B2 (bg) |
| KR (1) | KR20030077551A (bg) |
| CN (1) | CN100340545C (bg) |
| AR (1) | AR035659A1 (bg) |
| AU (2) | AU2002216074C1 (bg) |
| BG (1) | BG107889A (bg) |
| BR (1) | BR0115988A (bg) |
| CA (1) | CA2430355A1 (bg) |
| CZ (1) | CZ20031833A3 (bg) |
| EC (1) | ECSP034642A (bg) |
| HR (1) | HRP20030451A2 (bg) |
| HU (1) | HUP0400579A2 (bg) |
| IL (1) | IL156133A0 (bg) |
| MA (1) | MA26972A1 (bg) |
| MX (1) | MXPA03004947A (bg) |
| NO (1) | NO20032531L (bg) |
| NZ (1) | NZ526051A (bg) |
| PL (1) | PL365324A1 (bg) |
| RU (1) | RU2288220C2 (bg) |
| SK (1) | SK8512003A3 (bg) |
| WO (1) | WO2002046144A1 (bg) |
| YU (1) | YU45803A (bg) |
| ZA (1) | ZA200304262B (bg) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6822267B1 (en) * | 1997-08-20 | 2004-11-23 | Advantest Corporation | Signal transmission circuit, CMOS semiconductor device, and circuit board |
| US6706686B2 (en) * | 2001-09-27 | 2004-03-16 | The Regents Of The University Of Colorado | Inhibition of histone deacetylase as a treatment for cardiac hypertrophy |
| AU2002340253C1 (en) * | 2001-10-16 | 2011-03-31 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases and cancer of the brain |
| US7148257B2 (en) | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
| CN101259120B (zh) | 2002-03-04 | 2012-07-04 | Hdac默克研究有限责任公司 | 辛二酰苯胺异羟肟酸或其可药用盐在制备诱导末期分化的药物的用途 |
| US7456219B2 (en) | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
| AU2003226014A1 (en) * | 2002-03-28 | 2003-10-13 | Brigham And Women's Hospital, Inc. | Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease |
| US8673888B2 (en) * | 2002-04-05 | 2014-03-18 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Depsipeptide for therapy of kidney cancer |
| AU2003226408B2 (en) * | 2002-04-15 | 2007-06-14 | Sloan-Kettering Institute For Cancer Research | Combination therapy for the treatment of cancer |
| GB0217777D0 (en) * | 2002-07-31 | 2002-09-11 | Novartis Ag | Organic compounds |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7250514B1 (en) | 2002-10-21 | 2007-07-31 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| CA2508052A1 (en) * | 2002-12-05 | 2004-06-17 | Imperial College Innovations Limited | Control of apoptosis using a complex of an oligonucleotide and a regulatory peptide |
| US7381825B2 (en) * | 2003-03-17 | 2008-06-03 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| SI1663194T1 (sl) | 2003-08-26 | 2010-08-31 | Merck Hdac Res Llc | Uporaba SAHA za zdravljenje mezotelioma |
| CN102349927A (zh) | 2003-08-29 | 2012-02-15 | Hdac默克研究有限责任公司 | 联合治疗癌症的方法 |
| US20050159470A1 (en) * | 2003-12-19 | 2005-07-21 | Syrrx, Inc. | Histone deacetylase inhibitors |
| US20050137234A1 (en) * | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
| EP1734999A2 (en) * | 2004-04-05 | 2006-12-27 | Myogen, Inc. | Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure |
| EP1755649A1 (en) * | 2004-04-14 | 2007-02-28 | Medical Research Council | Selective killing of cancer cells by induction of acetyltransferase via tnf-alpha and il-6 |
| KR100632800B1 (ko) | 2004-10-21 | 2006-10-16 | 한국화학연구원 | 히스톤 디아세틸라제 저해활성을 갖는 신규한하이드록시아마이드 유도체 및 이의 제조 방법 |
| EP1824831A2 (en) * | 2004-12-16 | 2007-08-29 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| EP1896436A2 (en) * | 2005-05-11 | 2008-03-12 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| TWI415603B (zh) | 2005-05-20 | 2013-11-21 | Merck Sharp & Dohme | １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法 |
| EA200800321A1 (ru) * | 2005-07-14 | 2008-06-30 | Такеда Сан Диего, Инк. | Ингибиторы гистондеацетилазы |
| EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| JP2009525955A (ja) * | 2006-01-13 | 2009-07-16 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2012801A4 (en) | 2006-04-24 | 2009-08-05 | Gloucester Pharmaceuticals Inc | GEMCITABINE COMBINATION THERAPY |
| JP2009536667A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス，インコーポレイティド | ５ｈｔ受容体介在性の神経新生 |
| EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| AU2007292848A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US10184933B2 (en) | 2013-10-01 | 2019-01-22 | The J. David Gladstone Industries | Compositions, systems and methods for gene expression noise drug screening and uses thereof |
| EP3769757A3 (en) * | 2013-10-18 | 2021-10-06 | The General Hospital Corporation | Imaging histone deacetylases with a radiotracer using positron emission tomography |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| EP3461488A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dbait molecule and a hdac inhibitor for treating cancer |
| EP3946299A4 (en) * | 2019-03-29 | 2022-11-23 | Taiwanj Pharmaceuticals Co., Ltd. | BENZENE DERIVATIVES EXTENDED WITH PERIPHERAL ALKYL AND ALKENYL CHAIN EXTENDED AND PHARMACEUTICAL COMPOSITIONS THEREOF |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US20250134952A1 (en) | 2021-09-20 | 2025-05-01 | Institut National de la Santé et de la Recherche Médicale | Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor |
| CN119546293A (zh) | 2022-04-05 | 2025-02-28 | 国家癌症研究所Irccs-G·帕斯卡莱基金会 | Hdac抑制剂和他汀类药物的组合用于治疗胰腺癌 |
| WO2025026925A1 (en) | 2023-07-28 | 2025-02-06 | Ospedale San Raffaele S.R.L. | Gtf2i inhibitors and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4448730A (en) * | 1981-03-24 | 1984-05-15 | Riet Bartholomeus Van T | Hydroxybenzohydroxamic acids, benzamides and esters and related compounds as ribonucleotide reductase inhibitors |
| JPS61176523A (ja) * | 1985-01-30 | 1986-08-08 | Teruhiko Beppu | 制癌剤 |
| US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US5637946A (en) * | 1993-10-28 | 1997-06-10 | Lockheed Corporation | Thermally energized electrical power source |
| AUPO721997A0 (en) | 1997-06-06 | 1997-07-03 | Queensland Institute Of Medical Research, The | Anticancer compounds |
-
2001
- 2001-11-27 AR ARP010105504A patent/AR035659A1/es not_active Application Discontinuation
- 2001-12-04 US US10/006,173 patent/US6531472B2/en not_active Expired - Fee Related
- 2001-12-06 HR HR20030451A patent/HRP20030451A2/hr not_active Application Discontinuation
- 2001-12-06 NZ NZ526051A patent/NZ526051A/xx unknown
- 2001-12-06 JP JP2002547883A patent/JP4091431B2/ja not_active Expired - Fee Related
- 2001-12-06 CA CA002430355A patent/CA2430355A1/en not_active Abandoned
- 2001-12-06 CZ CZ20031833A patent/CZ20031833A3/cs unknown
- 2001-12-06 BR BR0115988-7A patent/BR0115988A/pt not_active IP Right Cessation
- 2001-12-06 MX MXPA03004947A patent/MXPA03004947A/es active IP Right Grant
- 2001-12-06 YU YU45803A patent/YU45803A/sh unknown
- 2001-12-06 AU AU2002216074A patent/AU2002216074C1/en not_active Ceased
- 2001-12-06 CN CNB018197345A patent/CN100340545C/zh not_active Expired - Fee Related
- 2001-12-06 PL PL01365324A patent/PL365324A1/xx not_active Application Discontinuation
- 2001-12-06 HU HU0400579A patent/HUP0400579A2/hu unknown
- 2001-12-06 RU RU2003119658/04A patent/RU2288220C2/ru active
- 2001-12-06 WO PCT/EP2001/014311 patent/WO2002046144A1/en not_active Ceased
- 2001-12-06 KR KR10-2003-7007640A patent/KR20030077551A/ko not_active Ceased
- 2001-12-06 AU AU1607402A patent/AU1607402A/xx active Pending
- 2001-12-06 SK SK851-2003A patent/SK8512003A3/sk unknown
- 2001-12-06 EP EP01999552A patent/EP1349830A1/en not_active Withdrawn
- 2001-12-06 IL IL15613301A patent/IL156133A0/xx unknown
-
2003
- 2003-05-30 ZA ZA200304262A patent/ZA200304262B/en unknown
- 2003-06-04 NO NO20032531A patent/NO20032531L/no not_active Application Discontinuation
- 2003-06-04 MA MA27193A patent/MA26972A1/fr unknown
- 2003-06-05 EC EC2003004642A patent/ECSP034642A/es unknown
- 2003-06-06 BG BG107889A patent/BG107889A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU1607402A (en) | 2002-06-18 |
| IL156133A0 (en) | 2003-12-23 |
| KR20030077551A (ko) | 2003-10-01 |
| RU2288220C2 (ru) | 2006-11-27 |
| CA2430355A1 (en) | 2002-06-13 |
| AU2002216074B2 (en) | 2006-01-05 |
| JP4091431B2 (ja) | 2008-05-28 |
| CN1478072A (zh) | 2004-02-25 |
| ZA200304262B (en) | 2004-08-30 |
| US6531472B2 (en) | 2003-03-11 |
| HK1060875A1 (en) | 2004-08-27 |
| AR035659A1 (es) | 2004-06-23 |
| CZ20031833A3 (cs) | 2004-02-18 |
| EP1349830A1 (en) | 2003-10-08 |
| YU45803A (sh) | 2006-05-25 |
| NO20032531D0 (no) | 2003-06-04 |
| WO2002046144A1 (en) | 2002-06-13 |
| HUP0400579A2 (hu) | 2004-06-28 |
| NZ526051A (en) | 2004-12-24 |
| ECSP034642A (es) | 2003-07-25 |
| BG107889A (bg) | 2004-06-30 |
| MA26972A1 (fr) | 2004-12-20 |
| AU2002216074C1 (en) | 2006-12-07 |
| BR0115988A (pt) | 2004-01-13 |
| PL365324A1 (en) | 2004-12-27 |
| MXPA03004947A (es) | 2003-09-10 |
| SK8512003A3 (en) | 2004-04-06 |
| CN100340545C (zh) | 2007-10-03 |
| JP2004515488A (ja) | 2004-05-27 |
| HRP20030451A2 (en) | 2005-04-30 |
| US20020065282A1 (en) | 2002-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20032531L (no) | Tetralon-derivater som antitumormidler | |
| Snieckus et al. | Intramolecular. alpha.-amidoyl-to-aryl 1, 5-hydrogen atom transfer reactions. Heteroannulation and. alpha.-nitrogen functionalization by radical translocation | |
| BG101422A (bg) | Бензоксазолни производни като бронхоразширяващи средства | |
| DE60304059D1 (de) | 3-(2-hydroxy-phenyl)-1h-pyrazol-4-carbonsäureamid derivate als hsp90 inhibitoren zur behandlung von krebs | |
| MXPA04005350A (es) | Compuesto de dibencilamina, y uso medicinal del mismo. | |
| NO973198L (no) | Aryl- og heteroarylpurinforbindelser | |
| MY131297A (en) | Herbicides | |
| EP4257137A3 (en) | Polycyclic carbamoylpyridone derivatives for the treatment of hiv | |
| BR0315405A (pt) | Compostos inibidores da integrase tricìclica pré-organizados | |
| YU20199A (sh) | Heterociklični sukcinimidi i njihova primena kao metaloproteinaznih inhibitora | |
| NO980154L (no) | Sykliske GMP-spesifikke fosfodiesteraseinhibitorer | |
| HUP0402454A2 (hu) | Szubsztituált kinazolinszármazékok mint az aurora kinázok inhibitorai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| WO2005092858A3 (en) | Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist | |
| GB1457385A (en) | Substituted formamidines process for their preparation and their use as uv stabilisers | |
| NO20044633L (no) | Nye alkoksypyridinderivater | |
| ES436665A1 (es) | Un procedimiento de preparacion de derivados de 3-(tiazol-2-oxi)-propanol. | |
| DK0656001T3 (da) | Nye 2-substituerede indan-2-mercaptoacetylamid-tricycliske derivater til anvendelse som enkefalinasehæmmere | |
| GB925429A (en) | Indole derivatives | |
| ES8206462A1 (es) | Un metodo para preparar derivados de 2-oxoazetidina. | |
| GB1428226A (en) | Process for the prepataion of aromatic hydroxylamines in the presence of catalysts | |
| ES2101887T3 (es) | Procedimiento microbiologico para la hidroxilacion de acidos carboxilicos con heterociclo nitrogenado. | |
| ES419661A1 (es) | Un procedimiento de preparacion de hidrazonas. | |
| BR0307424A (pt) | Compostos heterocìclicos com atividade inibidora de elastase e seus intermediários | |
| GB1054655A (bg) | ||
| MX9800705A (es) | Compuestos heterociclicos, composiciones para tratar isquemia de miocardio que los contiene, y procedimiento para su preparacion. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |